XRCC1和ERCC1与食管鳞状细胞癌放疗疗效及预后的相关性分析-肿瘤学专业论文.docx

— — PAGE 1— 摘 要 XRCC1 和 ERCC1 与食管鳞状细胞癌放疗疗效及 预后的相关性研究 研究生：刘珊珊 导师：张瑾熔 副教授 摘 要 目的：探讨食管鳞状细胞癌（ESCC）癌组织中 X 线修复交叉互补基因 1（XRCC1）、 切除修复交叉互补基因 1（ERCC1）的蛋白表达与放射治疗疗效及预后的相关性。方 法：采用免疫组织化学 SP 法检测了 59 例治疗前 ESCC 组织和 23 例癌旁组织标本中 XRCC1、ERCC1 的蛋白表达，结合临床病理特征和随访数据进行分析。结果：XRCC1、 ERCC1 蛋白主要表达于细胞核，两者表达无明显相关性。XRCC1 蛋白在 ESCC 组织 和癌旁组织中的阳性表达率分别为 52.5％和 13.0％，P＝0.001。ERCC1 蛋白在 ESCC 组织和癌旁组织中的阳性表达率分别为 33.9％和 65.2％，P＝0.010。XRCC1 蛋白在 汉族组和少数民族组阳性表达率分别为 72.2％和 43.9％，P＝0.045。ERCC1 蛋白在 无淋巴结转移组和有淋巴结转移组阳性表达率分别为 48.3％和 20.0％，P＝0.022。 XRCC1 表达阴性组的近期放疗有效率为 92.9％，较阳性组的 80.6％略有升高，P＝ 0.323。ERCC1 表达阳性组和阴性组患者的中位生存期分别为 13.2 个月(95％CI： 10.1～16.3)、21.4 个月(95％CI：19.1～23.7)，P＝0.001。多因素分析显示 ERCC1 表 达、病变长度与患者的生存期密切相关，是独立的预后因素（P＝0.001、0.037）。结 论：XRCC1、ERCC1 的蛋白表达情况可能在食管癌的发生中起一定作用。ERCC1 的蛋白表达与食管癌的淋巴结转移及放射治疗预后密切相关，其阳性表达是预后不 良的标志。 关键词：食管肿瘤；放射治疗；XRCC1；ERCC1；预后 新疆医科大学医学硕士学位论文 A Correlation Study of XRCC1 and ERCC1 to the Effect of Radiotherapy and Prognosis in Esophageal Squamous Cell Carcinoma Postgraduate: Liu Shanshan Supervisor: Professor Zhang Jinrong Abstract Objective: To analyze the relationship between the protein expressions of X-ray repair cross-complementing 1, excision repair cross complementing 1 and the effect of radiotherapy and prognosis in esophageal squamous cell carcinoma (ESCC). Methods: The protein expression of XRCC1 and ERCC1 in 59 samples of ESCC tissues and 23 adjacent tissues were examined using SP immunohistochemical staining and were analyzed according to the clinic pathologic features and follow-up data. Results: XRCC1 and ERCC1 protein were expressed in the nucleus of tumor cells in ESCC. There were no correlation between the expression of XRCC1 and ERCC1. The positive expression rate of XRCC1 protein in ESCC and adjacent tissues were 52.5％ and 13.0％, respectively（P＝ 0.001）. The positive expression rate of ERCC1 protein in ESCC and adjacent tissues were 33.9％and 65.2％, respectively（P＝0.010）. The positive expression rate of XRCC1 protein in the group of Han nation and the group of minority were 7